$2.18
0.91% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US09060U5074
Symbol
BCDA
Sector
Industry

BioCardia Inc. Stock price

$2.18
-0.56 20.44% 1M
+0.10 4.81% 6M
+0.00 0.00% YTD
-1.47 40.27% 1Y
-49.57 95.79% 5Y
-161.44 98.67% 10Y
-1,990.42 99.89% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.02 0.91%
ISIN
US09060U5074
Symbol
BCDA
Sector
Industry

Key metrics

Market capitalization $11.29m
Enterprise Value $10.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.45m
Free Cash Flow (TTM) Free Cash Flow $-8.11m
Cash position $950.00k
EPS (TTM) EPS $-1.81
P/E forward negative
Short interest 0.50%
Show more

Is BioCardia Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

BioCardia Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BioCardia Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BioCardia Inc.:

Buy
100%

Financial data from BioCardia Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.78 3.78
12% 12%
-
- Research and Development Expense 4.68 4.68
29% 29%
-
-8.39 -8.39
19% 19%
-
- Depreciation and Amortization 0.06 0.06
25% 25%
-
EBIT (Operating Income) EBIT -8.45 -8.45
19% 19%
-
Net Profit -8.39 -8.39
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about BioCardia Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioCardia Inc. Stock News

Neutral
GlobeNewsWire
24 days ago
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia's CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Direc...
Neutral
Seeking Alpha
about one month ago
Start Time: 16:30 January 1, 0000 5:01 PM ET BioCardia, Inc. (NASDAQ:BCDA ) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Company Participants Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Conference Call Participants Joe Pantginis - H.C. Wainwright Laura Suriel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
Neutral
GlobeNewsWire
about one month ago
SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The C...
More BioCardia Inc. News

Company Profile

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.

Head office United States
CEO Peter Altman
Employees 19
Founded 1994
Website www.biocardia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today